Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:55 AM
Ignite Modification Date:
2025-12-25 @ 3:55 AM
NCT ID:
NCT00000802
Eligibility Criteria:
Inclusion Criteria
Concurrent Medication: Strongly recommended:
* Pyrimethamine (50 mg) and folinic acid (15 mg) weekly in patients receiving dapsone who have CD4 count \< 100 cells/mm3 and are toxoplasmosis seropositive.
Patients must have:
* Working diagnosis of HIV infection.
* CD4 count \<= 200 cells/mm3 or \<= 15 percent of total lymphocyte count at any time in the past OR a history of PCP.
* History of intolerance of trimethoprim and/or sulfonamides that required permanent discontinuation.
NOTE:
* Pregnant patients are eligible at the clinician's discretion.
Prior Medication:
Allowed:
* Prior PCP prophylaxis.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
* Active pneumocystosis.
Concurrent Medication:
Excluded:
* PCP prophylaxis (other than study drug) or any medication with potential anti-PCP activity.
Patients with the following prior conditions are excluded:
* Known treatment-limiting reaction to dapsone or atovaquone.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
13 Years
Study:
NCT00000802
Study Brief:
Protocol Section:
NCT00000802